GeoVax Raises $863K Through 634,658-Warrant Exercise at $1.36, Issues 1.27M New Warrants
GeoVax agreed to inducement terms for immediate exercise of 634,658 warrants at $1.36, raising $863,000 in gross proceeds. Investors will get new warrants for 1,269,316 shares at $1.36 exercisable after shareholder approval and expiring five years later, with net funds intended for working capital.
1. Transaction Terms
GeoVax entered into a warrant inducement agreement with healthcare-focused institutional investors for the immediate exercise of up to 634,658 existing warrants at a reduced exercise price of $1.36 per share, generating approximately $863,000 in gross proceeds before fees and expenses. The closing is expected on or about April 1, 2026, subject to customary conditions.
2. New Warrants Details
In exchange for the immediate warrant exercise, investors will receive unregistered new warrants to purchase up to 1,269,316 shares of common stock at the same $1.36 exercise price. These new warrants become exercisable upon shareholder approval and will expire five years after the approval date.
3. Use of Proceeds
GeoVax intends to deploy the net proceeds from the transaction toward working capital and general corporate purposes, bolstering its financial position as it advances its clinical programs.
4. Company Background
GeoVax Labs is a clinical-stage biotechnology company developing vaccines against infectious diseases like mpox and smallpox, with a Phase 3 pivotal trial planned in H2 2026, and oncology immunotherapies including its Gedeptin gene-directed enzyme prodrug therapy and next-generation COVID-19 vaccine candidate.